Durect Corporation (DRRX) - Total Liabilities
Based on the latest financial reports, Durect Corporation (DRRX) has total liabilities worth $8.54 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Durect Corporation annual equity growth to track the company's year-over-year net asset growth rate.
Durect Corporation - Total Liabilities Trend (1999–2024)
This chart illustrates how Durect Corporation's total liabilities have evolved over time, based on quarterly financial data. See DRRX cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Durect Corporation Competitors by Total Liabilities
The table below lists competitors of Durect Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Fineblanking Technology Co Ltd
TWO:1586
|
Taiwan | NT$1.87 Billion |
|
Gold Terra Resource Corp
V:YGT
|
Canada | CA$2.18 Million |
|
JAKS Resources Bhd
KLSE:4723
|
Malaysia | RM837.51 Million |
|
Youngbo Chem
KO:014440
|
Korea | ₩20.15 Billion |
|
Ni Steel
KO:008260
|
Korea | ₩245.61 Billion |
|
VITA 34 AG
XETRA:V3V
|
Germany | €162.84 Million |
|
DocGo Inc
NASDAQ:DCGO
|
USA | $98.02 Million |
|
Fortune Oriental Co Ltd
TW:2491
|
Taiwan | NT$347.60 Million |
Liability Composition Analysis (1999–2024)
This chart breaks down Durect Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Durect Corporation worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Durect Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Durect Corporation (1999–2024)
The table below shows the annual total liabilities of Durect Corporation from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $9.22 Million | -69.68% |
| 2023-12-31 | $30.41 Million | -13.41% |
| 2022-12-31 | $35.12 Million | +2.65% |
| 2021-12-31 | $34.21 Million | -3.71% |
| 2020-12-31 | $35.53 Million | -43.75% |
| 2019-12-31 | $63.16 Million | +110.54% |
| 2018-12-31 | $30.00 Million | -5.14% |
| 2017-12-31 | $31.62 Million | -1.69% |
| 2016-12-31 | $32.17 Million | +0.88% |
| 2015-12-31 | $31.89 Million | +1.01% |
| 2014-12-31 | $31.57 Million | +212.60% |
| 2013-12-31 | $10.10 Million | +5.15% |
| 2012-12-31 | $9.60 Million | -78.99% |
| 2011-12-31 | $45.72 Million | -13.86% |
| 2010-12-31 | $53.07 Million | +72.68% |
| 2009-12-31 | $30.73 Million | -20.08% |
| 2008-12-31 | $38.45 Million | -22.22% |
| 2007-12-31 | $49.44 Million | -24.47% |
| 2006-12-31 | $65.45 Million | -11.62% |
| 2005-12-31 | $74.06 Million | +10.41% |
| 2004-12-31 | $67.08 Million | -0.32% |
| 2003-12-31 | $67.29 Million | +891.19% |
| 2002-12-31 | $6.79 Million | -14.01% |
| 2001-12-31 | $7.89 Million | +47.35% |
| 2000-12-31 | $5.36 Million | +208.82% |
| 1999-12-31 | $1.74 Million | -- |
About Durect Corporation
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment… Read more